Studies on meperidine-induced catalepsy in mice

Area of Science:

• Neuropharmacology
• Drug Discovery

Background:

• Catalepsy is a motor control disorder characterized by akinesia and rigidity.
• Meperidine, an opioid analgesic, can induce catalepsy in animal models.
• Understanding the neurochemical pathways involved in catalepsy is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the anticataleptic effects of various pharmacological agents against meperidine-induced catalepsy in mice.
• To explore the roles of monoamine oxidase (MAO), dopaminergic, GABAergic, and serotoninergic systems in meperidine-induced catalepsy.

Main Methods:

• Meperidine (50 mg/kg, intraperitoneal) was administered to induce catalepsy in mice.
• The anticataleptic effects of MAO inhibitors (clorgyline, selegiline), alpha-2 agonists, and agents modulating dopaminergic, GABAergic, and serotoninergic neurotransmission were evaluated.
• The efficacy of naloxone, an opioid antagonist, was also assessed.

Main Results:

• Monoamine oxidase (MAO) inhibitors (A and B), alpha-2 agonists, and dopaminergic, GABAergic, and serotoninergic agents significantly attenuated meperidine-induced cataleptic symptoms.
• Naloxone, an opiate antagonist, did not reverse the meperidine-induced akinesia and rigidity.
• The MAO-A inhibitor clorgyline demonstrated greater potency than the MAO-B inhibitor selegiline in reducing catalepsy.

Conclusions:

• The study highlights the involvement of MAO, dopaminergic, GABAergic, and serotoninergic systems in the mechanism of meperidine-induced catalepsy.
• Opioid receptors are not primarily responsible for the catalepsy induced by meperidine.
• MAO-A inhibitors represent a promising therapeutic strategy for managing drug-induced catalepsy.